Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof
AssigneeMemorial Sloan Kettering Cancer Center
InventorsTaha Merghoub, Jedd D. Wolchok, Daniel H. Cymerman, Cailian Liu
Life of this patent
Estimating the term…
Abstract
The presently disclosed subject matter provides methods and compositions for treating cancer (e.g., melanoma). It relates to chimeric antigen receptors (CARs) that specifically target MDA (e.g., Trp1), and immunoresponsive cells comprising such CARs. The presently disclosed MDA-specific CARs have enhanced immune-activating properties, including anti-tumor activity.
Claims49
A chimeric antigen receptor (CAR), comprising an extracellular antigen-binding domain, a transmembrane domain and an intracellular domain, wherein the extracellular antigen-binding domain specifically binds to a melanoma differentiation antigen (MDA) polypeptide.
-10. (canceled)
-17. (canceled)
-24. (canceled)
-29. (canceled)
(canceled)
(canceled)
-37. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-59. (canceled)
-78. (canceled)
-85. (canceled)
Dependencies are inferred from the claim text.